Faoud T. Ishmael
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Faoud T. Ishmael has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Alanna N Roff
Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, The Pennsylvania State University Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States of America
3 shared publicationsAlanna N. Roff
Department of Biostatistics and Informatics, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colo
3 shared publications- Cristiana Stellato
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana” University of Salerno Salerno Italy
3 shared publications - Kristin A. Lambert
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
3 shared publications - Ronaldo Paolo Panganiban
Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA
3 shared publications Avery August
Department of Microbiology and Immunology, Cornell University, Ithaca, NY
2 shared publications
Latest Publications
- 28 May 2024
- Published by Elsevier in Medical Clinics of North America
- Vol. 108 (4) , 671-685
Penicillin Allergy
- 28 May 2024
- Published by Elsevier in Medical Clinics of North America
- Vol. 108 (4) , 671-685
Penicillin Allergy
- 25 February 2024
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 132 (6) , 723-729.e4
Plasma microRNAs as biomarkers in hereditary angioedema
- 25 February 2024
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 132 (6) , 723-729.e4
Plasma microRNAs as biomarkers in hereditary angioedema
- Open Access
- 22 November 2023
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 3 (1) , 100196
Identification of biologic-responsive phenotypes in elderly people with eosinophilic asthma
- 22 November 2023
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 3 (1) , 100196
Open AccessIdentification of biologic-responsive phenotypes in elderly people with eosinophilic asthma
- Open Access
- 6 October 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (19) , 7287
Effects of Inhaled Corticosteroids and Particle Size on Risk of Obstructive Sleep Apnea: A Large Retrospective Cohort Study
Background: Inhaled corticosteroids (ICS) produce local effects on upper airway dilators that could increase the risk of developing obstructive sleep apnea (OSA). Given that the particle size of ICS changes their distribution, the particle size of ICS may impact the risk of developing OSA. Objectives: In this large retrospective study, we explore the relationship of ICS use and OSA in patients with asthma. In addition, we seek to determine if this relationship is affected by the particle size of ICS. Methods: Using electronic health records, we established a cohort of 29,816 asthmatics aged 12 and older with a diagnosis of asthma documented by ICD-9 or ICD-10 codes between January 2011 and August 2016. We performed analyses of variance and multivariate logistic regression analysis to determine the effects ICS on the diagnosis of OSA with sub-analysis by particle size of ICS. Results: Uncontrolled asthmatics showed increased odds of receiving a diagnosis of OSA whether when looking at ACT scores (adjusted odds ratio (aOR) 1.60, 95% CI 1.32–1.94) or PFT results (aOR 1.45, 95% CI 1.19–1.77). Users of ICS also had increased odds of OSA independent of asthma control (aOR 1.58, 95% CI 1.47–1.70). Notably, users of extra-fine particle ICS did not have significantly increased odds of having OSA compared to non-users of ICS (aOR 1.11, 95% CI 0.78–1.58). Conclusions: Use of ICS appears to be an independent risk factor for OSA. Notably, extra-fine particle size ICS do not appear to be associated with an increased risk of OSA.
- 6 October 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (19) , 7287
Open AccessEffects of Inhaled Corticosteroids and Particle Size on Risk of Obstructive Sleep Apnea: A Large Retrospective Cohort Study
Background: Inhaled corticosteroids (ICS) produce local effects on upper airway dilators that could increase the risk of developing obstructive sleep apnea (OSA). Given that the particle size of ICS changes their distribution, the particle size of ICS may impact the risk of developing OSA. Objectives: In this large retrospective study, we explore the relationship of ICS use and OSA in patients with asthma. In addition, we seek to determine if this relationship is affected by the particle size of ICS. Methods: Using electronic health records, we established a cohort of 29,816 asthmatics aged 12 and older with a diagnosis of asthma documented by ICD-9 or ICD-10 codes between January 2011 and August 2016. We performed analyses of variance and multivariate logistic regression analysis to determine the effects ICS on the diagnosis of OSA with sub-analysis by particle size of ICS. Results: Uncontrolled asthmatics showed increased odds of receiving a diagnosis of OSA whether when looking at ACT scores (adjusted odds ratio (aOR) 1.60, 95% CI 1.32–1.94) or PFT results (aOR 1.45, 95% CI 1.19–1.77). Users of ICS also had increased odds of OSA independent of asthma control (aOR 1.58, 95% CI 1.47–1.70). Notably, users of extra-fine particle ICS did not have significantly increased odds of having OSA compared to non-users of ICS (aOR 1.11, 95% CI 0.78–1.58). Conclusions: Use of ICS appears to be an independent risk factor for OSA. Notably, extra-fine particle size ICS do not appear to be associated with an increased risk of OSA.
- 1 July 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 144 (1) , 315-317
Dust mite induces leukocyte exosomes with proinflammatory effects toward airway epithelial cells
- 1 July 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 144 (1) , 315-317
Dust mite induces leukocyte exosomes with proinflammatory effects toward airway epithelial cells
- Open Access
- 1 January 2019
- Published by OAE Publishing Inc.
Emerging role of MicroRNAs in allergic diseases
Journal of Translational Genetics and Genomics is an open access journal, publishing articles related to single gene disorders, rare genetic disease, specific genetic syndromes, complex disease, etc.
- 1 January 2019
- Published by OAE Publishing Inc.
Open AccessEmerging role of MicroRNAs in allergic diseases
Journal of Translational Genetics and Genomics is an open access journal, publishing articles related to single gene disorders, rare genetic disease, specific genetic syndromes, complex disease, etc.
- Open Access
- 9 October 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (10) , e0205434
MicroRNA-146a is induced by inflammatory stimuli in airway epithelial cells and augments the anti-inflammatory effects of glucocorticoids
MicroRNAs (miRNAs) are emerging as central regulators of inflammation, but their role in asthma and airway epithelial cells is not well studied. Glucocorticoids are the cornerstone of therapy in asthma and other inflammatory disease, yet their mechanisms of action are not completely elucidated, and it is not clear whether miRNAs modulate their effects. We aimed to identify miRNAs that regulate cytokine and chemokine expression in airway epithelial cells and whether these miRNAs are subject to the effects of glucocorticoids. MicroRNAomic analyses of immortalized, normal human bronchial epithelial cells identified 7 miRNAs that were altered by inflammatory cytokine treatment and 22 that were regulated by glucocorticoids (n = 3 for each treatment condition). MiR-146a emerged as a central candidate, whose expression was induced by TNF-α and repressed by glucocorticoids. Its role as a candidate in asthmatic inflammation was supported by expression profiling in human asthmatics, which showed that plasma miR-146a expression was elevated in asthma and associated with measures related to worse asthma outcomes, including elevated blood eosinophil counts, higher asthma control questionnaire scores, and need for higher doses of inhaled glucocorticoids. However, transfection of miR-146a in A549 cells treated with TNF-α +/- glucocorticoids produced an anti-inflammatory effect and increased efficacy of glucocorticoids. We propose a model whereby miR-146a is induced by inflammatory conditions as a feedback mechanism to limit inflammation. Exogenous administration of miR-146a augmented the effects of glucocorticoids and could be a novel therapeutic strategy to enhance efficacy of these medications.
- 9 October 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (10) , e0205434
Open AccessMicroRNA-146a is induced by inflammatory stimuli in airway epithelial cells and augments the anti-inflammatory effects of glucocorticoids
MicroRNAs (miRNAs) are emerging as central regulators of inflammation, but their role in asthma and airway epithelial cells is not well studied. Glucocorticoids are the cornerstone of therapy in asthma and other inflammatory disease, yet their mechanisms of action are not completely elucidated, and it is not clear whether miRNAs modulate their effects. We aimed to identify miRNAs that regulate cytokine and chemokine expression in airway epithelial cells and whether these miRNAs are subject to the effects of glucocorticoids. MicroRNAomic analyses of immortalized, normal human bronchial epithelial cells identified 7 miRNAs that were altered by inflammatory cytokine treatment and 22 that were regulated by glucocorticoids (n = 3 for each treatment condition). MiR-146a emerged as a central candidate, whose expression was induced by TNF-α and repressed by glucocorticoids. Its role as a candidate in asthmatic inflammation was supported by expression profiling in human asthmatics, which showed that plasma miR-146a expression was elevated in asthma and associated with measures related to worse asthma outcomes, including elevated blood eosinophil counts, higher asthma control questionnaire scores, and need for higher doses of inhaled glucocorticoids. However, transfection of miR-146a in A549 cells treated with TNF-α +/- glucocorticoids produced an anti-inflammatory effect and increased efficacy of glucocorticoids. We propose a model whereby miR-146a is induced by inflammatory conditions as a feedback mechanism to limit inflammation. Exogenous administration of miR-146a augmented the effects of glucocorticoids and could be a novel therapeutic strategy to enhance efficacy of these medications.
- Open Access
- 1 August 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (3) , 916-929
miR-155 Modulates Cockroach Allergen– and Oxidative Stress–Induced Cyclooxygenase-2 in Asthma
Exposure to cockroach allergen is a strong risk factor for developing asthma. Asthma has been associated with allergen-induced airway epithelial damage and heightened oxidant stress. In this study, we investigated cockroach allergen–induced oxidative stress in airway epithelium and its underlying mechanisms. We found that cockroach extract (CRE) could induce reactive oxygen species (ROS) production, particularly mitochondrial-derived ROS, in human bronchial epithelial cells. We then used the RT2 Profiler PCR array and identified that cyclooxygenase-2 (COX-2) was the most significantly upregulated gene related to CRE-induced oxidative stress. miR-155, predicted to target COX-2, was increased in CRE-treated human bronchial epithelial cells, and was showed to regulate COX-2 expression. Moreover, miR-155 can bind COX-2, induce COX-2 reporter activity, and maintain mRNA stability. Furthermore, CRE-treated miR-155−/− mice showed reduced levels of ROS and COX-2 expression in lung tissues and PGE2 in bronchoalveolar lavage fluid compared with wild-type mice. These miR-155−/− mice also showed reduced lung inflammation and Th2/Th17 cytokines. In contrast, when miR-155−/− mice were transfected with adeno-associated virus carrying miR-155, the phenotypic changes in CRE-treated miR-155−/− mice were remarkably reversed, including ROS, COX-2 expression, lung inflammation, and Th2/Th17 cytokines. Importantly, plasma miR-155 levels were elevated in severe asthmatics when compared with nonasthmatics or mild-to-moderate asthmatics. These increased plasma miR-155 levels were also observed in asthmatics with cockroach allergy compared with those without cockroach allergy. Collectively, these findings suggest that COX-2 is a major gene related to cockroach allergen–induced oxidative stress and highlight a novel role of miR-155 in regulating the ROS–COX-2 axis in asthma.
- 1 August 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (3) , 916-929
Open AccessmiR-155 Modulates Cockroach Allergen– and Oxidative Stress–Induced Cyclooxygenase-2 in Asthma
Exposure to cockroach allergen is a strong risk factor for developing asthma. Asthma has been associated with allergen-induced airway epithelial damage and heightened oxidant stress. In this study, we investigated cockroach allergen–induced oxidative stress in airway epithelium and its underlying mechanisms. We found that cockroach extract (CRE) could induce reactive oxygen species (ROS) production, particularly mitochondrial-derived ROS, in human bronchial epithelial cells. We then used the RT2 Profiler PCR array and identified that cyclooxygenase-2 (COX-2) was the most significantly upregulated gene related to CRE-induced oxidative stress. miR-155, predicted to target COX-2, was increased in CRE-treated human bronchial epithelial cells, and was showed to regulate COX-2 expression. Moreover, miR-155 can bind COX-2, induce COX-2 reporter activity, and maintain mRNA stability. Furthermore, CRE-treated miR-155−/− mice showed reduced levels of ROS and COX-2 expression in lung tissues and PGE2 in bronchoalveolar lavage fluid compared with wild-type mice. These miR-155−/− mice also showed reduced lung inflammation and Th2/Th17 cytokines. In contrast, when miR-155−/− mice were transfected with adeno-associated virus carrying miR-155, the phenotypic changes in CRE-treated miR-155−/− mice were remarkably reversed, including ROS, COX-2 expression, lung inflammation, and Th2/Th17 cytokines. Importantly, plasma miR-155 levels were elevated in severe asthmatics when compared with nonasthmatics or mild-to-moderate asthmatics. These increased plasma miR-155 levels were also observed in asthmatics with cockroach allergy compared with those without cockroach allergy. Collectively, these findings suggest that COX-2 is a major gene related to cockroach allergen–induced oxidative stress and highlight a novel role of miR-155 in regulating the ROS–COX-2 axis in asthma.
- 1 May 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (3) , 750-756
Characterization of Vancomycin Reactions and Linezolid Utilization in the Pediatric Population
- 1 May 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (3) , 750-756
Characterization of Vancomycin Reactions and Linezolid Utilization in the Pediatric Population
- 1 May 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (5) , 1423-1432
Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma
- 1 May 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (5) , 1423-1432
Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma